• 1
    Monahan B. P., Ferguson C. L., Killeavy E. S., Lloyd B. K., Troy J., Cantilena L. R. Jr. Torsade de pointes occurring in association with terfenadine use. JAMA 1990; 264: 27882790.
  • 2
    Deamer R. L., Wilson D. R., Clark D. S., Prichard J. G. Torsade de pointes associated with high dose levomethadyl acetate (ORLAAM). J Addict Dis 2001; 20: 714.
  • 3
    Krantz M. J., Lewkowiez L., Hays H., Woodroffe M. A., Robertson A. D., Mehler P. S. Torsades de pointes associated with very high dose methadone. Ann Intern Med 2002; 137: 501504.
  • 4
    Katchman A. N., McGroary K. A., Kilborn M. J., Kornick C. A., Manfredi P. L., Woosley R. L. et al. Influence of opioid agonists on cardiac human ether-a-go-go related gene K+ currents. J Pharmacol Exp Ther 2002; 303: 688694.
  • 5
    Pearson E. C., Woosley R. L. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. Pharmacoepidemiol Drug Saf 2005; 14: 747753.
  • 6
    Poluzzi E., Raschi E., Moretti U., De Ponti F. Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). Pharmacoepidemiol Drug Saf 2009; 18: 512518.
  • 7
    Patel A. M., Singh J. P., Ruskin J. N. Role of implantable cardioverter-defibrillators in patients with methadone-induced long QT syndrome. Am J Cardiol 2008; 101: 209211.
  • 8
    Hanon S., Seewald R. M., Yang F., Schweitzer P., Rosman J. Ventricular arrhythmias in patients treated with methadone for opioid dependence. J Interv Card Electrophysiol 2010; 28: 1922.
  • 9
    Wedam E., Bigelow G. E., Johnson R. E., Nuzzo P. A., Haigney MCP QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med 2007; 167: 24692475.
  • 10
    Chugh S. S., Socoteanu C., Reinier K., Waltz J., Jui J., Gunson K. A community-based evaluation of sudden death associated with therapeutic levels of methadone. Am J Med 2008; 121: 6671.
  • 11
    Centers for Disease Control and Prevention (CDC). Vital signs: risk for overdose from methadone used for pain relief—United States, 1999–2010. Morb Mortal Wkly Rep 2012; 61: 493497.
  • 12
    Anchersen K., Clausen T., Gossop M., Hansteen V., Waal H. Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study. Addiction 2009; 104: 993999.
  • 13
    Kao D. P., Katz D. F., Bucher-Bartleson B., Mehler P. S., Krantz M. J. Methadone-associated ventricular arrhythmia fatalities reported to the FDA from 1969–2011. Heart Rhythm 2012; 9: S89. AB40–05 [Abstract].
  • 14
    Krantz M. J., Martin J., Stimmel B., Mehta D., Haigney M. C. QTc interval screening in methadone treatment. Ann Intern Med 2009; 150: 387395.
  • 15
    Drew B. J., Ackerman M. J., Funk M., Gibler W. B., Kligfield P., Menon V. et al., American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology; Council on Cardiovascular Nursing, American College of Cardiology Foundation. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation 2010; 121: 10471060.
  • 16
    Martin J. A., Campbell A., Killip T., Kotz M., Krantz M. J., Kreek M. J. et al., Substance Abuse and Mental Health Services Administration (SAMHSA). QT interval screening in methadone maintenance treatment: report of a SAMHSA expert panel. J Addict Dis 2011; 30: 283306.
  • 17
    Roden D. M. Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350: 10131022.